Pixium Vision is developing retinal implant systems for patients who have lost their sight, with the intention of improving their vision and enabling them to lead more independent lives. The Company intends to harness the rapid advances being made in neural processing, micro-electronics and computing to develop retinal implant systems that for blind people could ultimately provide vision approaching that of a normal healthy Pixium's first device, IRIS1 (Intelligent Retinal Implantable System), uses an epi-retinal implant (on the retinal surface) and is currently in clinical trials with the goal of obtaining CE Mark. A second generation system (IRIS2) based on the same format, but offering better visual acuity and featuring several breakthrough technologies, is also under development. In addition, Pixium is developing a sub-retinal implant system (IRIS3), based on further technological breakthroughs, which has the potential to improve vision significantly compared to IRIS1 and IRIS2. Pixium was created in Paris, France in November 2011 as a spin-out of the Vision Institute and Université Pierre et Marie Curie, and based on collaborative work involving several leading academic teams across Europe. Pixium is backed by a syndicate of blue-chip European venture capital firms including Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Seventure and Polytechnos.

Retina Implant AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals and institutes which began with a large grant from the German Federal Ministry of Research and Education in 1996, Retina Implant AG was founded by Dr. Eberhart Zrenner and his colleagues in 2003 with private investors with the goal of developing the first fully-functioning electronic retinal implant to restore useful vision to the blind. Retina Implant began implanting in human patients in 2005, and has started a second clinical trial this year.

Optobionics Corp. develops artificial retina and related devices to restore vision for individuals afflicted with retinitis pigmentosa, age-related macular degeneration, and other outer retinal diseases that can lead to blindness. It was founded by Alan Y. Chow and Vincent Y. Chow in 1990. The company is headquartered in Naperville, IL.

IMI Intelligent Medical Implants is a medical technology company. The goal of the company is to develop and market an intelligent retinal implant system for degenerative retinal disorders such as Retinitis Pigmentosa or Macular Degeneration and thereby make a contribution to the improvement of the quality of life of blind people. Through the combination of innovative technology from the medical device, IT and micro systems fields, a new class of active medical products has been created allowing, amongst other things, blind people to regain modest visual perception. The company was founded in 2002 and has 30 employees.\nThe company has a process oriented quality management system in accordance with ISO 13485.

Nano Retina, a joint venture of Zyvex Labs (www.zyvexlabs.com), and Rainbow Medical (www.rainbowmedical.co.il), is developing Bio-Retina, a bionic retina designed to restore sight to those suffering from retinal degenerative diseases. Bio-Retina incorporates various nano-size components in one tiny, flat implant, approximating the size of a child’s fingernail bed. Its simple 30-minute implant procedure requires local anesthesia, a small incision and “gluing” of the device to the damaged retina. Return of sight is anticipated to be instantaneous: 20/200 with the first generation and 20/20 with the second generation product, enabling persons who have undergone the procedure to watch TV and identify faces. Recovery time is estimated at up to one week.

Carl Zeiss AG (German: [kaʁl tsaɪs]), branded as ZEISS, is a German manufacturer of optical systems and optoelectronics, founded in Jena, Germany in 1846 by optician Carl Zeiss. Together with Ernst Abbe (joined 1866) and Otto Schott (joined 1884) he laid the foundation for today's multi-national company. The current company emerged from a reunification of Carl Zeiss companies in East and West Germany with a consolidation phase in the 1990s. ZEISS is active in four business segments with approximately equal revenue, Industrial Quality and Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology in almost 50 countries, has 30 production sites and around 25 development sites worldwide.

Vivani Medical manufactures and markets implantable visual prosthetics to enable blind individuals to achieve greater independence. It creates a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations, such as Retinitis Pigmentosa. Through dedication and innovation, Second Sight's mission is to develop, manufacture, and market implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight Medical Products located in Sylmar, California, and was founded in 1998.

Lambdavision, Inc. develops a high-resolution protein-based retinal prosthesis for the restoration of vision. It provides solutions for in the development of a retinal implant for those afflicted with retinal degenerative diseases. The company was founded by Robert R. Birge in May, 2009 and is headquartered in Farmington, CT.

Doheny Eye Institute is an American private company located in Los Angeles, CA. The firm provides eye care related research and education programs. Marissa Goldberg is currently the CEO of the company.\nThe company says this about itself: For more than 70 years, Doheny Eye Institute has been at the forefront of vision science. From seeking new ways to free blockages that prevent fluid drainage in glaucoma, to replacing retinal cells in age-related macular degeneration, to providing colleagues worldwide with standardized analyses of anatomical changes in the eyes of patients, Doheny clinician-scientists and researchers are changing how people see �� and also how they think about the future of vision. Doheny Eye Institute and UCLA Stein Eye Institute have joined forces to offer the best patient care, vision research, and education. This affiliation combines the strength, reputation, and distinction of two of the nation's top eye institutions to advance vision research, education, and patient care in California.

AD Verwaltungs GmbH & Co. KG is a German private company located in Gr��nwald. The firm provides management services.

Cortigent, Inc. engages in developing targeted neurostimulation systems to help patients recover critical body functions. The company was founded in November 2022 and is headquartered in Valencia, CA.

Weizhi Medical Equipment Co., Ltd., established on 2018-03-26, Business scope includes prosthetics,artificial organs and implants(between)into device manufacturing;Prosthetics and Orthotics(assistive devices)production assembly;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;Class III Medical Devices,Production of Class II Medical Devices;Class III Medical Devices,Sales of Class II Medical Devices;Class III Medical Devices,R&D of Class II medical devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

NewCyte, Inc. portfolio of intellectual property includes several issued and pending patents covering the coating of fullerenes with silica, dielectric and/or semiconducting films for a variety of potential applications, including photon, chemical and biomolecule sensing.\nThe potential end uses for these technologies include new devices in photovoltaic (solar cells), portable biochemical analysis and artificial retinas. Its research is early stage, the potential applications are compelling.

Verily aspires to create a world in which technology and life sciences are not distinct, but partners with a united mission. Formerly Google Life Sciences, Verily's mission is to bring together technology and life sciences to uncover new truths about health and disease. Verily's multidisciplinary teams have access to advanced research tools, large-scale computing power, and unique technical expertise. They work with partners from across the industry and many fields of research to develop new technology, launch studies and start companies. The company was founded in 2015 and is based in San Francisco, California, United States.

Nanochap is a biomedical technology developed through core chip research and development. They are regarded as one of the forerunners in the field of resolution artificial retina having been involved in the research of this cutting-edge technology since its inception. They enable clients to monitor human physiological parameters and efficiently analyze personal health status.

CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l'énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. The total CEA workforce consisted of 15 838 employees. Across the whole of the CEA (including both civilian and military research), there were 1556 PhD students and 293 post-docs. The CEA is based in ten research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France and Burgundy. The CEA benefits from the strong regional identities of these laboratories and the partnerships forged with other research centers, local authorities and universities.

Engages in the development and domestic implantable medical devices

Thomas RECORDING is a manufacturer and distributor of microelectrodes and microdrives for neuroscience.

Eyevation LLC focuses on improving the treatment of retinal degenerative diseases. It is a medical device company and its initial product is a surgical instrument for treating these diseases. The company was founded by Norman D. Radtke on February 18, 2009 and is headquartered in Louisville, KY.